@article{oai:repo.qst.go.jp:00047472,
 author = {Kobayashi, Masato and Nishii, Ryuichi and Shikano, Naoto and G, Flores Leo and Mizutani, Asuka and Ogai, Kazuhiro and Sugama, Jyunko and Nagamachi, Shigeki and Kawai, Keiichi and 西井 龍一},
 issue = {6},
 journal = {Nuclear medicine and biology},
 month = {Feb},
 note = {A specific diagnosis for melanoma is strongly desired because malignant melanoma has poor prognosis. In a previous study, although radioiodine-125-labeled 4-hydroxyphenyl-L-cysteine ((125)I-L-PC) was found to have good substrate affinity for tyrosinase enzyme in the melanin metabolic pathway, (123/131)I-L-PC had insufficient substrate affinity for tyrosinase to diagnose melanoma. In this study, we synthesized 4-hydroxyphenylcysteamine (4-PCA) and developed a novel radioiodine-125-labeled 4-hydroxyphenylcysteamine ((125)I-PCA) to increase affinity for the melanin biosynthesis pathway.},
 pages = {536--540},
 title = {Development of radioiodine-labeled 4-hydroxyphenylcysteamine for specific diagnosis of malignant melanoma.},
 volume = {42},
 year = {2015}
}